Pernilla M. Wikstrom
Umea, AC, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Correction: Pro-neuropeptide Y as a circulating biomarker for poor prognosis in prostate cancer.
Journal: Scientific reports
Published: July 15, 2026
MicroRNA profiles of prostate cancer bone metastases and miR-375 as an inhibitor of the aggressive metastasis subtype MetB.
Journal: Scientific reports
Published: January 29, 2026
Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095.
Journal: BMC cancer
Published: January 21, 2026
Pro-neuropeptide Y as a circulating biomarker for poor prognosis in prostate cancer.
Journal: Scientific reports
Published: January 14, 2026
Morphological heterogeneities in prostate cancer bone metastases are related to molecular subtypes and prognosis.
Journal: Clinical & experimental metastasis
Published: April 10, 2025
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer.
Journal: Molecular oncology
Published: July 04, 2024
Metabolic readouts of tumor instructed normal tissues (TINT) identify aggressive prostate cancer subgroups for tailored therapy.
Journal: Frontiers in molecular biosciences
Published: May 02, 2024
Molecular subtypes provide possibilities for precision medicine in a advanced prostate cancer
Journal: Lakartidningen
Published: April 24, 2024
Toll-like receptor-2 induced inflammation causes local bone formation and activates canonical Wnt signaling.
Journal: Frontiers in immunology
Published: February 06, 2024
Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer.
Journal: Acta oncologica (Stockholm, Sweden)
Published: September 15, 2023
Last Updated: 09/26/2026